OLMA Olema Pharmaceuticals, Inc.
FY2025 10-K
Olema Pharmaceuticals, Inc. (OLMA) filed its fiscal year 2025 10-K annual report with the SEC on Mar 16, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biopharma developing next-generation targeted therapies for ER+ breast cancer, emphasizing oral small molecule endocrine therapies
- • New emphasis: Initiated pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy (2023) and Phase 3 OPERA-02 trial with ribociclib combination (2025)
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in the provided MD&A excerpt
- • No segment performance data available in the provided text
Risk Factors
- • FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
- • Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations
Get deeper insights on Olema Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.